Niagen Bioscience Inc

Given the decisive break below the 3.61 support with elevated volume and extended EMAs, the downtrend remains intact across all horizons. Long-term and medium-term biases are bearish. Short-term conditions favor execution now. We will sell into the breakdown, leveraging momentum continuation dynamics.

• ↑Q1’26 revenue $31.5M (+5% YoY); 2026 growth guidance 10–15%.
• ↑Cash $66.5M, zero debt supports R&D and market expansion.
• ↓FDA ruling on NMN opens flood of competitors, threatens margins.